Rating: Weekly View

Related Articles by Louis Navellier

Company Profile

Medivation, Inc., a biopharmaceutical company, focuses on developing novel small molecule drugs for the treatment of serious diseases in the United States and Europe. The company’s lead development candidate includes MDV3100, a molecule, which is in Phase-III development for the treatment of castration-resistant prostate cancer. Medivation, Inc. has collaboration with Astellas for the development, manufacture, and commercialization of MDV3100 for the treatment of prostate cancer. The company was founded in 2003 and is headquartered in San Francisco, California.